A Dose Escalation Study of Intensity Modulated Total Marrow Irradiation (IMRT-TMI) with Fludarabine as a Myeloablative Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Relapsed and Refractory Hematologic Malignancies
Naoyuki Saito, MD
Primary Investigator
Brief description of study
Detailed description of study
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: acute myeloid leukemia,acute lymphocytic leukemia,myelodysplasia
-
Age: Between 18 Years - 65 Years
-
Gender: All
Inclusion Criteria
Patients must be diagnosed with one of the following conditions:
Acute Myeloid Leukemia (AML) who are not incomplete remission, and who have either primary refractory or relapsed disease
Acute Lymphocytic Leukemia (ALL) who are not in complete remission, and who have either primary refractory or relapsed disease
Myelodysplasia
Exclusion Criteria
Patients with ALL who are in second or subsequent relapse
Active infection: Patients with active infections requiring oral or intravenous antimicrobial drugs are not eligible for enrollment until resolution of infection.
HIV seropositive patients.
Pregnant or nursing females are excluded from this study.
Prior radiation therapy*Patients who have had a prior autologous or allogeneic bone marrow or stem cell transplantation
Find a site
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
Primary Contact
